Testing a new biomarker for Xuebijing injection in sepsis
Part of Infections clinical trials.
This study looks at a Chinese herbal injection called Xuebijing to see if certain biomarkers can predict how well it works for sepsis patients. It may help find new ways to treat sepsis more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with sepsis (Sepsis 3.0 criteria).
- Your SOFA score (a measure of organ failure) is between 2 and 12.
- You are between 18 and 75 years old.
- You are not pregnant or breastfeeding.
- You do not have severe diseases like cancer, serious blood disorders, or HIV.
- You have not used immunosuppressants or had an organ transplant in the last 6 months.
- You do not have a recent heart attack or conditions that affect blood vessel health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether Xuebijing injection improves outcomes for adults with sepsis. It looks at how well the treatment works in everyday hospital care, not just in a controlled research setting.
This trial tests if Shenhuang granules, a traditional Chinese medicine, can help treat sepsis (a life-threatening response to infection). It aims to see if it improves outcomes for patients with sepsis.
This trial studies people with and without sepsis in the ICU to understand why some get very sick from infections. It aims to find better ways to predict who will have complications and guide treatment.
This trial is testing whether certain biomarkers (substances in your body) can help diagnose sepsis faster. Sepsis is a serious condition where your body has a severe response to an infection. The study will look at blood or other samples to see if these markers can quickly tell if you have sepsis, which could lead to faster treatment.
This study looks at the outcomes of people hospitalized with sepsis in China. It helps doctors understand how patients respond to treatment and what factors affect recovery.
This trial tests whether Shenfu injection can improve the flexibility of blood vessels in people with severe infections (sepsis or septic shock). It may help understand how to better support the heart and circulation during critical illness.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.